Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti kumar V, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21(1):499. https://doi.org/10.1186/s12935-021-02202-5.
Article CAS PubMed PubMed Central Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Article CAS PubMed Google Scholar
Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57. https://doi.org/10.1016/j.apsb.2021.09.006.
Article CAS PubMed Google Scholar
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75. https://doi.org/10.1001/jamainternmed.2017.3601.
Article PubMed PubMed Central Google Scholar
Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011.
Article CAS PubMed Google Scholar
Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol. 2021;68:8–20. https://doi.org/10.1016/j.semcancer.2019.09.012.
Article CAS PubMed Google Scholar
Basso J, Miranda A, Sousa J, Pais A, Vitorino C. Repurposing drugs for glioblastoma: from bench to bedside. Cancer Lett. 2018;428:173–83. https://doi.org/10.1016/j.canlet.2018.04.039.
Article CAS PubMed Google Scholar
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–83. https://doi.org/10.1182/blood-2016-09-736686.
Article CAS PubMed PubMed Central Google Scholar
Dimopoulos MA, Kastritis E. Thalidomide for myeloma: still here? Lancet Haematol. 2018;5(10):e439–40. https://doi.org/10.1016/S2352-3026(18)30154-6.
Liu Q, Tong D, Liu G, Gao J, Wang LA, Xu J, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24(22):5622–34. https://doi.org/10.1158/1078-0432.CCR-18-0420.
Article CAS PubMed Google Scholar
Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). The Lancet. 2000;355(9208):1022. https://doi.org/10.1016/s0140-6736(05)74775-9.
Kresge N, Simoni RD, Hill RL. The rational design of nucleic acid inhibitors to treat leukemia: the work of George H. Hitchings. J Biol Chem. 2008;283(18):e10–11.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–6. https://doi.org/10.1038/nrd2199.
Article CAS PubMed Google Scholar
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. https://doi.org/10.1038/s41392-021-00572-w.
Article PubMed PubMed Central Google Scholar
Gonzalez-Fierro A, Dueñas-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–31. https://doi.org/10.1016/j.semcancer.2019.12.012.
Medema MH, Fischbach MA. Computational approaches to natural product discovery. Nat Chem Biol. 2015;11(9):639–48. https://doi.org/10.1038/nchembio.1884.
Article CAS PubMed PubMed Central Google Scholar
Baltz RH. Natural product drug discovery in the genomic era: realities, conjectures, misconceptions, and opportunities. J Ind Microbiol Biotechnol. 2019;46(3–4):281–99. https://doi.org/10.1007/s10295-018-2115-4.
Article CAS PubMed Google Scholar
Hur M, Campbell AA, Almeida-de-Macedo M, Li L, Ransom N, Jose A, et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Nat Prod Rep. 2013;30(4):565–83. https://doi.org/10.1039/c3np20111b.
Article CAS PubMed PubMed Central Google Scholar
Biermann F, Wenski SL, Helfrich EJN. Navigating and expanding the roadmap of natural product genome mining tools. Beilstein J Org Chem. 2022;18:1656–71. https://doi.org/10.3762/bjoc.18.178.
Article CAS PubMed PubMed Central Google Scholar
Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering anti-cancer drugs via computational methods. Front Pharmacol. 2020;11:733. https://doi.org/10.3389/fphar.2020.00733.
Article CAS PubMed PubMed Central Google Scholar
Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM. Application of computational methods for anticancer drug discovery, design, and optimization. Bol Med Hosp Infant Mex. 2016;73(6):411–23. https://doi.org/10.1016/j.bmhimx.2016.10.006.
Article PubMed PubMed Central Google Scholar
Baldi A. Computational approaches for drug design and discovery: an overview. Syst Rev Pharm. 2010;1(1):99–105. https://doi.org/10.4103/0975-8453.59519.
Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91–97. https://doi.org/10.4103/2278-330X.110506.
Article PubMed PubMed Central Google Scholar
Selassie C, Verma RP. History of quantitative structure-activity relationships. Burger’s Med Chem Drug Discov. 2003;1:1–48. https://doi.org/10.1002/0471266949.bmc001.pub2.
Mendenhall J, Meiler J. Improving quantitative structure-activity relationship models using Artificial Neural Networks trained with dropout. J Comput Aided Mol Des. 2016;30(2):177–89. https://doi.org/10.1007/s10822-016-9895-2.
Article CAS PubMed PubMed Central Google Scholar
Esposito EX, Hopfinger AJ, Madura JD. Methods for applying the quantitative structure-activity relationship paradigm. Methods Mol Biol. 2004;275:131–214. https://doi.org/10.1385/1-59259-802-1:131.
Article CAS PubMed Google Scholar
Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol. 2008;443:365–82. https://doi.org/10.1007/978-1-59745-177-2_19.
Article CAS PubMed Google Scholar
Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019;7:83–9. https://doi.org/10.1007/s40484-019-0172-y.
Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010-2011 in review. J Mol Recognit. 2013;26(5):215–39. https://doi.org/10.1002/jmr.2266.
Article CAS PubMed Google Scholar
Dias R, de Azevedo Jr WF. Molecular docking algorithms. Curr Drug Targets. 2008;9(12):1040–7. https://doi.org/10.2174/138945008786949432.
Article CAS PubMed Google Scholar
Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem. 2016;16(19):2156–68. https://doi.org/10.2174/1568026616666160216153618.
Article CAS PubMed Google Scholar
Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. https://doi.org/10.1038/s41392-020-00213-8.
Article PubMed PubMed Central Google Scholar
Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 2010;65(5):895–902. https://doi.org/10.1007/s00280-009-1095-5.
Article CAS PubMed Google Scholar
Zhou X, Sun WJ, Wang WM, Chen K, Zheng JH, Lu MD, et al. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs. 2013;24(9):920–7. https://doi.org/10.1097/CAD.0b013e328364a109.
留言 (0)